X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs AJANTA PHARMA - Comparison Results

LUPIN    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN AJANTA PHARMA LUPIN/
AJANTA PHARMA
 
P/E (TTM) x 39.2 21.8 179.5% View Chart
P/BV x 2.4 4.1 58.0% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 LUPIN   AJANTA PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-18
AJANTA PHARMA
Mar-18
LUPIN/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4651,818 80.6%   
Low Rs7271,106 65.7%   
Sales per share (Unadj.) Rs349.6239.5 146.0%  
Earnings per share (Unadj.) Rs5.652.8 10.5%  
Cash flow per share (Unadj.) Rs29.659.5 49.7%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs300.3230.0 130.6%  
Shares outstanding (eoy) m452.0888.77 509.3%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.16.1 51.4%   
Avg P/E ratio x197.227.7 712.1%  
P/CF ratio (eoy) x37.124.6 150.8%  
Price / Book Value ratio x3.66.4 57.4%  
Dividend payout %90.00-   
Avg Mkt Cap Rs m495,502129,782 381.8%   
No. of employees `00017.06.8 250.8%   
Total wages/salary Rs m28,6473,765 760.9%   
Avg. sales/employee Rs Th9,273.63,128.4 296.4%   
Avg. wages/employee Rs Th1,681.0554.0 303.4%   
Avg. net profit/employee Rs Th147.4689.7 21.4%   
INCOME DATA
Net Sales Rs m158,04221,258 743.5%  
Other income Rs m1,504242 622.3%   
Total revenues Rs m159,54521,499 742.1%   
Gross profit Rs m31,4756,584 478.1%  
Depreciation Rs m10,859596 1,822.2%   
Interest Rs m2,0444 49,841.5%   
Profit before tax Rs m20,0766,226 322.5%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,8851,539 187.4%   
Profit after tax Rs m2,5134,686 53.6%  
Gross profit margin %19.931.0 64.3%  
Effective tax rate %14.424.7 58.1%   
Net profit margin %1.622.0 7.2%  
BALANCE SHEET DATA
Current assets Rs m122,09512,236 997.8%   
Current liabilities Rs m50,9563,461 1,472.5%   
Net working cap to sales %45.041.3 109.0%  
Current ratio x2.43.5 67.8%  
Inventory Days Days8560 140.5%  
Debtors Days Days12084 141.9%  
Net fixed assets Rs m129,87611,140 1,165.9%   
Share capital Rs m904177 511.1%   
"Free" reserves Rs m134,86620,237 666.4%   
Net worth Rs m135,77120,414 665.1%   
Long term debt Rs m64,24510 636,089.1%   
Total assets Rs m263,05424,486 1,074.3%  
Interest coverage x10.81,519.4 0.7%   
Debt to equity ratio x0.50 95,638.8%  
Sales to assets ratio x0.60.9 69.2%   
Return on assets %1.719.2 9.0%  
Return on equity %1.923.0 8.1%  
Return on capital %3.730.5 12.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14111,667 455.5%   
Fx outflow Rs m19,3351,616 1,196.8%   
Net fx Rs m33,80710,052 336.3%   
CASH FLOW
From Operations Rs m17,5122,854 613.5%  
From Investments Rs m-14,073-2,604 540.4%  
From Financial Activity Rs m-14,921-2 746,045.0%  
Net Cashflow Rs m-11,482248 -4,627.9%  

Share Holding

Indian Promoters % 46.6 73.8 63.1%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 1.6 729.0%  
FIIs % 31.9 7.6 419.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 17.0 59.4%  
Shareholders   98,259 20,968 468.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   BIOCON   WOCKHARDT  VENUS REMEDIES  PLETHICO PHARMA  FDC LTD.  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)

Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.

Related Views on News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Jun 14, 2019 (Close)

TRACK LUPIN

LUPIN - WYETH LTD COMPARISON

COMPARE LUPIN WITH

MARKET STATS